Omegaven and essential fatty acid deficiency in children with liver problems from intravenous feeding
Watches for fatty acid deficiency in children given Omegaven for feeding-related cholestasis.
Key facts
- Who runs it
- Fresenius Kabi
- Where
- Boston, Chicago, Cincinnati, Fountain Valley, Houston, Los Angeles, Nashville, Oklahoma City, San Antonio, and Seattle, United StatesSee the 10 sites
- Trial code
- Registry title
- Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 15 Dec 2024
- Expected to end
- 1 Apr 2028
- Type of study
- Observational
- Treatments tested
- Omegaven® (fish oil triglycerides) Injectable Emulsion
- Record updated
- 14 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children under 18 with liver problems caused by long-term intravenous feeding (PNAC) who are expected to need Omegaven for at least eight weeks.
- Age
- From 1 day to 17 years (under 18).
- Sex
- Boys and girls can both join.
- Disease stage
- Parenteral nutrition-associated cholestasis (PNAC): direct or conjugated bilirubin (DBil) of 2.0 mg/dL or more, with no other known cause of liver problems. Must also have feeding intolerance by mouth or tube, or a gut disorder that needs intravenous feeding (PN).
- Earlier treatment
- Cannot have had Omegaven in the four weeks before joining. Cannot have had a liver transplant.
- Biomarker or test result
- Direct or conjugated bilirubin (DBil) of 2.0 mg/dL or more.
Main reasons for not taking part
- Another known cause of chronic liver disease, such as hepatitis C, cystic fibrosis or biliary atresia
- Known cirrhosis or portal vein thrombosis
- Past or current essential fatty acid deficiency (EFAD)
- Very high blood fats (triglycerides above 1,000 mg/dL (11.3 mmol/L))
- Allergy to fish or egg protein, or to any ingredient of Omegaven
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Patient's parent(s) or legal guardian(s) has provided a signed and dated Informed Consent Form (ICF)
- Pediatric patient (<18 years) has been diagnosed with PNAC, defined as direct or conjugated bilirubin (DBil) ≥ 2.0 mg/dL with no other known cause of liver dysfunction at the time of enrollment and is expected to require Omegaven treatment for at least eight weeks
- Patient has oral or enteral feeding intolerance or at least one gastrointestinal disorder requiring PN
Who cannot take part
- Patient has received Omegaven within four weeks before inclusion in the study
- Patient has been previously diagnosed with, or has prior evidence of, portal vein thrombosis
- Patient has previously received a liver-only or liver-inclusive transplant
- Patient has any other known cause of chronic liver disease such as hepatitis C, cystic fibrosis, biliary atresia, alpha-1-antitrypsin deficiency, passive hepatic congestion due to heart failure, etc
- Patient has hemodynamic instability due to any major cardiac anomaly
- Patient has a major life-threatening disease (e.g., sepsis requiring high-dose vasopressors, acute respiratory distress syndrome, veno-occlusive disease, cancer)
- Patient has multi-organ failure, septic shock, hypotension requiring pressor therapy, persistent pulmonary hypertension requiring inhaled nitric oxides, or requires extracorporeal membrane oxygenation (ECMO) or similar intervention
- Patient has renal failure and requires renal replacement therapy
- Patient has a severe hemorrhagic disorder
- Patient has a known hypersensitivity to fish or egg protein or to any of the active ingredients or excipients of Omegaven
- Patient has severe hyperlipidemia or a severe disorder of lipid metabolism characterized by hypertriglyceridemia (i.e., serum triglyceride level > 1,000 mg/dL)
- Patient has known cirrhosis (liver biopsy is not required under this protocol)
- Patient has a record of EFAD before inclusion in the study
- Patient has been diagnosed with or is suspected to have an inborn error of metabolism
- Patient is subject to treatment limitation
- Patient is enrolled in any other study with an investigational medicinal product during the course of the current study
Where in United States
- Children's Hospital Corporation d/b/a Boston Children's HospitalBoston, United StatesContact: Niess Ulf, PhDTaking people
- The University Of ChicagoChicago, United StatesContact: Niess Ulf, PhDTaking people
- Children's Hospital Medical CenterCincinnati, United StatesContact: Niess Ulf, PhDTaking people
- Memorial Health ServiceFountain Valley, United StatesContact: Niess Ulf, PhDTaking people
- Baylor College of Medicine, HoustonHouston, United StatesContact: Niess Ulf, PhDTaking people
- University of California, Los AngelesLos Angeles, United StatesContact: Niess Ulf, PhDTaking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Niess Ulf, PhDTaking people
- Board of Regents of the University of Oklahoma Health Sciences CenterOklahoma City, United StatesContact: Niess Ulf, PhDTaking people
- The University of Texas Health Science Center at San AntonioSan Antonio, United StatesContact: Niess Ulf, PhDTaking people
- Seattle Children's Hospital d/b/a Seattle Children's Research InstituteSeattle, United StatesContact: Niess Ulf, PhDTaking people
About the trial
What the trial wants to find out
This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population
The group in the trial
- Single arm OMEGAVEN® (fish oil triglycerides; injectable emulsion)
The dose of investigational drug (study treatment), as well as all other components of the overall nutritional regimen is solely at the discretion of the Investigator. It is assumed the Investigator will use sound medical judgement, follow institutional standards of care regarding the nutrition provided to each patient, and review applicable prescribing information indicating the maximum and recommended dose of Omegaven of 1 g/kg/day infused intravenously over 8 to 24 hours as long as the infusion rate does not exceed 1.5 mL/kg/hour.
Treatment: Omegaven® (fish oil triglycerides) Injectable Emulsion
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Title: A Single-arm, Open-label, Prospective, Multicenter Safety Study to Evaluate the Occurrence of Essential Fatty Acid Deficiency (EFAD) in Pediatric Patients With Parenteral Nutrition-associated Cholestasis (PNAC) Who Require More Than Eight Weeks of Omegaven Treatment
- Plain-language title
- Omegaven and essential fatty acid deficiency in children with liver problems from intravenous feedingGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 August 2026